A detailed history of Cibc Bancorp Usa Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Cibc Bancorp Usa Inc. holds 10,736 shares of SLS stock, worth $15,352. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,736
Holding current value
$15,352
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$1.54 - $2.17 $16,533 - $23,297
10,736 New
10,736 $17,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $29.4M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Cibc Bancorp Usa Inc. Portfolio

Follow Cibc Bancorp Usa Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Bancorp Usa Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cibc Bancorp Usa Inc. with notifications on news.